STOCK TITAN

Nurix Therapeutics: T. Rowe Price reports 4.4% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. was the subject of an amended Schedule 13G in which T. Rowe Price Associates, Inc. reported 4,570,774 shares, or 4.4% of the class, as beneficially owned as of September 30, 2026. The firm reported sole voting power over 4,422,815 shares and sole dispositive power over 4,570,774 shares, with no shared voting or dispositive power. It stated that the disclosure should not be construed as an admission of beneficial ownership and expressly denied such ownership; it also marked the category for ownership of 5% or less of the class.

Beneficially owned shares 4,570,774 shares T. Rowe Price Associates, Inc.; as of September 30, 2026
Percent of class 4.4% T. Rowe Price Associates, Inc.; as of September 30, 2026
Sole voting power 4,422,815 shares T. Rowe Price Associates, Inc.; as of September 30, 2026
Shared voting power 0 shares T. Rowe Price Associates, Inc.; as of September 30, 2026
Sole dispositive power 4,570,774 shares T. Rowe Price Associates, Inc.; as of September 30, 2026
Shared dispositive power 0 shares T. Rowe Price Associates, Inc.; as of September 30, 2026
beneficial ownership technical
"beneficial ownership is expressly denied"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole voting power technical
"Sole Voting Power 4,422,815.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power technical
"Sole Dispositive Power 4,570,774.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NRIX shares did T. Rowe Price Associates report?

T. Rowe Price Associates, Inc. reported 4,570,774 shares, or 4.4% of the class, as beneficially owned as of September 30, 2026. It reported sole voting power over 4,422,815 shares and sole dispositive power over 4,570,774 shares, while expressly denying beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





67080M103

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Associates, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:11/16/2026

Keep reading